Conditions

The Maestro Rechargeable System is indicated for treatment of patients aged at least 18 years with a BMI of 35 to 45 with at least one obesity-related condition and who have failed to lose weight on a weight loss program. The novel device is the first to target the nerve …

Steve Freed: Please tell us a little about yourself and this new compound, BTI320. Dr. David Platt: My area of expertise is the recognition between carbohydrate and protein. In my previous two companies, I developed drugs for a recognition between sugar and protein. In one case, it was a protein that …

Rudy Bilous, MD, FRCP Richard Donnelly, MD, PHD, FRCP, FRACP The vast majority of cases of diabetes in children are type 1, caused by autoimmune destruction of beta cells in the pancre­atic islets. A steady increase in the incidence of type 1 dia­betes has been reported worldwide (average increase 2.5-3% per year …

Janelle, an RN, is 36 years old with type 1 diabetes. She has a busy life between family and work. She eats healthy, exercises regularly, and wears a pump but occasionally has severe hypoglycemia, especially during exercise and at night. When I met her, I recommended she wear a continuous …

Change Talk: Childhood Obesity is a role-play simulation where you take the role of a healthcare provider and engage in a practice conversation with a virtual mother and her child. Through the conversation, you learn to apply Motivational Interviewing (MI) techniques to help them identify motivation for change, supporting them …

Glargine 300 more effective than glargine 100 currently available… Two single-dose studies were conducted in Japan and Europe to compare the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of new insulin glargine 300 U/ml (Gla-300) and insulin glargine 100 U/ml (Gla-100) in people with type 1 diabetes mellitus. In two double-blind, randomized, crossover …

Can metformin reduce the risk of cancer for those with type 2 diabetes?… In previous studies, metformin has been shown to decrease the risk of cancer in type 2 diabetes. A recent meta-analysis showed a 34% reduction in the incidence of any cancer and a 33% reduction in cancer mortality; …

Insulin resistance with increasing LDL cholesterol were related to low peak volume of oxygen level… Diabetic nephropathy and cardiovascular disease are strongly related in adults with type 1 diabetes, yet little is known about this relationship in adolescents prior to the onset of detectable clinical disease. The researchers hypothesized that …

Diabetic patients can lose weight with medication specific for weight loss... In two randomized, double-blind and placebo-controlled studies, the safety and efficacy of treatment with phentermine (PHEN) and topiramate ER (TPM ER) (Qsymia) plus lifestyle for weight loss and glycemic benefits were measured. The studies included obese/overweight adults with type 2 diabetes. …

The drug, a first-in-class MetAP2 inhibitor, was well-tolerated and also improved cardiovascular disease risk factors… Zafgen has announced that ZAF-221, a randomized, double-blind, placebo-controlled Phase 2 clinical trial of beloranib, a MetAP2 inhibitor, in 14 adults with hypothalamic injury associated obesity, or HIAO, met the primary efficacy endpoint of weight …